10.1021/acs.jnatprod.6b00203.s001
Sarath
P. Gunasekera
Sarath
P.
Gunasekera
Lorelie Imperial
Lorelie
Imperial
Christiana Garst
Christiana
Garst
Ranjala Ratnayake
Ranjala
Ratnayake
Long H. Dang
Long H.
Dang
Valerie J. Paul
Valerie J.
Paul
Hendrik Luesch
Hendrik
Luesch
Caldoramide, a Modified Pentapeptide from the Marine
Cyanobacterium <i>Caldora penicillata</i>
American Chemical Society
2016
Marine Cyanobacterium Caldora penicillata
HCT 116 colorectal cancer cells
marine cyanobacterium Caldora penicillata
Caldoramide
dolastatin
HIF
caldoramide
oncogenic KRAS
LCMS
2016-07-05 16:50:15
Journal contribution
https://acs.figshare.com/articles/journal_contribution/Caldoramide_a_Modified_Pentapeptide_from_the_Marine_Cyanobacterium_i_Caldora_penicillata_i_/3471329
The isolation, structure determination,
and biological activities
of a new linear pentapeptide, caldoramide (<b>5</b>), from the
marine cyanobacterium <i>Caldora penicillata</i> from Florida
are described. Caldoramide (<b>5</b>) has structural similarities
to belamide A (<b>4</b>), dolastatin 10 (<b>1</b>), and
dolastatin 15 (<b>2</b>). We profiled caldoramide against parental
HCT116 colorectal cancer cells and isogenic cells lacking oncogenic
KRAS or hypoxia-inducible factors 1α (HIF-1α) and 2α
(HIF-2α). Caldoramide (<b>5</b>) showed differential cytotoxicity
for cells containing both oncogenic KRAS and HIF over the corresponding
knockout cells. LCMS dereplication indicated the presence of caldoramide
(<b>5</b>) in a subset of <i>C. penicillata</i> samples.